| |
Giantcode is committed to developing innovative biophysical treatments for life threatening diseases like cancer. Focus is solely on destroying unwanted cells in the human body in an unconventional and groundbreaking manner. Our current clinical and preclinical programs all emanate from internal discoveries and are rooted in our scientific heritage and strength in biophysical research.
Core to Giantcode's strategy is to selectively pursue strategic collaborations to advance and maximize the commercial potential of our pipeline. In therapeutic areas that involve a more extensive development program or address large primary care markets, we intend to complete late-stage clinical development and commercialisation through, or in collaboration with, partners.
In areas where our products can be marketed by specialised biotech partners (i.e. by sub-licensing), we are interested in exploring commercial partnerships.
Additionally, for discoveries we have made that have applications outside our main focus area, we may explore partnerships earlier in the process to accelerate advancements and market launch.
|
|
